Madrigal Pharmaceuticals (MDGL) Amortization of Deferred Charges (2022 - 2026)
Madrigal Pharmaceuticals (MDGL) reported Amortization of Deferred Charges of $449000.0 for Q1 2026, up 2.98% year-over-year from $436000.0 in Q1 2025, and down 4.06% quarter-over-quarter from $468000.0 in Q4 2025.
Madrigal Pharmaceuticals (MDGL) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 5 years of Amortization of Deferred Charges data on file, last reported at $449000.0 in Q1 2026.
- Amortization of Deferred Charges for Q1 2026 came in at $449000.0, up 2.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (down 13.53% YoY), and the FY2025 annual result was $1.6 million, down 23.22% from the prior year.
- Amortization of Deferred Charges eased to $449000.0 in Q1 2026 per MDGL's latest filing, from $468000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $753000.0 in Q4 2023 and troughed at $178000.0 in Q2 2022.
- A 5-year average of $459562.5 and a median of $458500.0 in 2025 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges soared 211.24% in 2023, then tumbled 35.99% in 2024.
- A 5-year view of Amortization of Deferred Charges shows it stood at $306000.0 in 2022, then jumped by 146.08% to $753000.0 in 2023, then plunged by 35.99% to $482000.0 in 2024, then fell by 2.9% to $468000.0 in 2025, then decreased by 4.06% to $449000.0 in 2026.
- Business Quant data shows MDGL's Amortization of Deferred Charges at $449000.0 in Q1 2026, $468000.0 in Q4 2025, and $329000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 449,000.00 |
| Mar 31, 2026 | 449,000.00 |
| Dec 31, 2025 | 468,000.00 |
| Dec 31, 2025 | 468,000.00 |
| Sep 30, 2025 | 329,000.00 |
| Sep 30, 2025 | 329,000.00 |
| Jun 30, 2025 | 371,000.00 |
| Jun 30, 2025 | 371,000.00 |
| Mar 31, 2025 | 436,000.00 |
| Mar 31, 2025 | 436,000.00 |
| Dec 31, 2024 | 482,000.00 |
| Dec 31, 2024 | 482,000.00 |
| Sep 30, 2024 | 480,000.00 |
| Sep 30, 2024 | 480,000.00 |
| Jun 30, 2024 | 472,000.00 |
| Jun 30, 2024 | 472,000.00 |
| Mar 31, 2024 | 655,000.00 |
| Mar 31, 2024 | 655,000.00 |
| Dec 31, 2023 | 753,000.00 |
| Dec 31, 2023 | 753,000.00 |